Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1622 1625 1654
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | Non-Final OA | Genzyme Corporation |
| 18362386 | DINUCLEAR PHOSPHANE GOLD(I) COMPLEXES FOR TREATING CANCER | Non-Final OA | Imam Abdulrahman Bin Faisal University |
| 18255749 | OIL-IN-WATER EMULSIFIED COMPOSITION | Final Rejection | KAO CORPORATION |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Final Rejection | SHIONOGI & CO., LTD. |
| 17760181 | Agent For Treating Or Preventing Pancreatic Fistula | Final Rejection | NOF CORPORATION |
| 18564839 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | Non-Final OA | Universiteit Hasselt |
| 18558113 | HYDROXYBISPHOSPHONIC DERIVATIVES OF MELOXICAM FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES | Non-Final OA | Atlanthéra |
| 17915361 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Non-Final OA | NIPPON CHEMIPHAR CO., LTD. |
| 18547252 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | Non-Final OA | SYNAPTOGENIX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy